The vaccine candidate is set to enter clinical trials soon. Credit: Mirko Sajkov from Pixabay.

US-based (J&J) is in discussions with the Government of Japan, as well as the Bill and Melinda Gates Foundation, regarding allocations of its Covid-19 vaccine candidate.

In an interview with Reuters, J&J chief financial officer Joseph Wolk said that the company already agreed to an allocation deal with the US as part of its funding agreement with the US Biomedical Advanced Research and Development Authority (BARDA).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Bill and Melinda Gates Foundation intends to provide any vaccine it acquired to developing countries, noted Wolk. According to a previous report by Reuters, J&J is also in discussions with the European Union.

Wolk was quoted by the news agency as saying: 鈥淣othing has been finalised yet. We continue to have those discussions. People from the countries and the organisations we mentioned want to lock in a certain minimum level of capacity that they would get.鈥�

The ‘general construct’ of the talks is expected to be similar to 鈥檚 agreement with the US Government, which offered $1.2bn to support drug development in return for committing a delivery of around 300 million doses this year.

In addition, AstraZeneca received a contract from France, Germany, Italy and the Netherlands for up to 400 million doses of its Covid-19 vaccine candidate. The company also collaborated with non-profits for supply to developing countries.

Wolk added that these talks will help J&J fix a price for its vaccine, which the company plans to sell for no profit during the pandemic. The company intends to begin manufacturing later this year, based on its success in clinical trials.

In an earnings call on 16 July, J&J revealed plans to launch first human trials of its Covid-19 vaccine candidate on 22 July, with late-stage studies planned for September.